Medicure Inc.'s Pivotal Phase 3 MEND-CABG II Results to be Presented at Late-Breaking Session at the American College of Cardiology Conference

WINNIPEG, MANITOBA--(Marketwire - February 05, 2008) - Medicure, Inc. (TSX: MPH)(AMEX: MCU), a cardiovascular-focused biopharmaceutical company, today announced that the results of the Company's pivotal Phase 3 MEND-CABG II trial have been accepted for presentation as a Late-Breaking Clinical Trial at the American College of Cardiology 57th Annual Scientific Session. The Annual Scientific Session is being held March 29 to April 1, 2008 in Chicago.